Washington, D.C. 20549



Pursuant to Section 13 OR 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

January 20, 2021

Alector, Inc.

(Exact name of registrant as specified in its charter)






(State or other jurisdiction of incorporation)


(Commission File Number)


(IRS Employer
Identification No.)

131 Oyster Point Blvd. Suite 600

South San Francisco, California 94080

(Address of principal executive offices, including zip code)


(415) 231-5660
(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:




Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock


The Nasdaq Stock Market LLC

(The Nasdaq Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  




 Item 7.01.  Regulation FD Disclosure.

Alector, Inc. announced on January 20, 2021, the transition of chief business officer (CBO), Sabah Oney, Ph.D., effective as of February 1, 2021. Dr. Oney will remain as an employee and advisor until May 3, 2021, to assist with the transition. A copy of the press release related to Dr. Oney’s transition is attached hereto as Exhibit 99.1.

All of the information furnished in this Item 7.01 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.



Press release dated January 20, 2021.







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.









Date: January 20, 2021



/s/ Arnon Rosenthal




Arnon Rosenthal, Ph.D.




Co-founder and Chief Executive Officer




Exhibit 99.1


Alector Announces Departure of Chief Business Officer


Sabah Oney steps down as from a role held since January 2018; joined Alector in October 2016


The departure will be effective February 1, 2021; will assist in transition until May 3, 2021


SOUTH SAN FRANCISCO, Calif., Jan. 20, 2021 -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that chief business officer (CBO), Sabah Oney, Ph.D., will be leaving the Company to pursue other opportunities.

Shehnaaz Suliman M.D., MBA, M.Phil., president and chief operating officer, will serve as interim CBO, overseeing the business development, finance, communications, facilities, and IT departments. The transition will be effective as of February 1, 2021 and Dr. Oney will remain as an employee and advisor to Alector until May 3, 2021.


“Alector was a private, pre-clinical biotech company with less than 20 employees when Sabah joined in 2016. Since then, the Company has continued to grow quickly, thanks in part to Sabah’s leadership,” said Arnon Rosenthal, Ph.D., co-founder and chief executive officer of Alector. “On behalf of the entire Board and executive team, we thank Sabah for his contributions at several critical stages for the company and wish him well in all future endeavors.”


I am proud to have been part of Alector these past four years. It has been a privilege to support the growth of this dynamic and truly innovative company,” said Dr. Oney. “I am confident the team will continue building on the strong foundation already established and maintain the Company’s momentum as it seeks to discover and deliver innovative therapies for some of the most devastating neurodegenerative diseases.”


About Alector

Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. The Company is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. Immunoneurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The Company’s immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. This scientific approach is also the basis for the Company’s immuno-oncology programs. Alector is headquartered in South San Francisco, California. For additional information, please visit


Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from current expectations and beliefs, including but not limited to risks and uncertainties related to market conditions, Alector and its business as set forth in Alector’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 10, 2020, as well as the other documents Alector files from time

to time with the SEC. These documents contain and identify important factors that could cause the actual results for Alector to differ materially from those contained in Alector’s forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alector specifically disclaims any obligation to update any forward-looking statement, except as required by law.





Erica Jefferson

Vice President, Communications and Public Affairs

Alector, Inc.




Dan Budwick





Alector, Inc.